• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $NVAX

    Novavax Inc.

    Subscribe to $NVAX
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. In addition, the company develops vaccine candidates for the protection against middle east respiratory syndrome, as well as that is in preclinical work associated with severe acute respiratory syndrome; and ebola virus glycoprotein vaccine candidate, as well as COVID-19 vaccine for variant strain. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

    IPO Year:

    Exchange: NASDAQ

    Website: novavax.com

    Peers

    $BVXV
    $MRNA

    Recent Analyst Ratings for Novavax Inc.

    DatePrice TargetRatingAnalyst
    2/28/2025$19.00Buy
    BTIG Research
    7/30/2024$8.00Neutral → Underweight
    JP Morgan
    5/10/2024$4.00 → $12.00Underperform → Neutral
    BofA Securities
    5/10/2024Underweight → Neutral
    JP Morgan
    8/9/2023$15.00Neutral → Buy
    B. Riley Securities
    4/20/2023$55.00 → $10.00Outperform → Market Perform
    TD Cowen
    3/1/2023$29.00 → $10.00Buy → Neutral
    B. Riley Securities
    1/9/2023$74.00 → $37.00Buy
    B. Riley Securities
    12/30/2022$207.00 → $110.00Buy
    H.C. Wainwright
    12/2/2022Hold
    Jefferies
    See more ratings

    Novavax Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Novavax Reports First Quarter 2025 Financial Results and Operational Highlights

      FDA feedback on COVID-19 BLA suggests pathway to approval upon alignment on study parameters for the postmarketing commitment requested by FDASHIELD-Utah study demonstrates that Nuvaxovid® resulted in fewer and less severe reactogenicity symptoms when compared to marketed mRNA vaccine; Nuvaxovid recipients experienced approximately 39% fewer symptoms on averageData presented at World Vaccine Congress showcases Matrix-M® utility when co-administered with a broad array of vaccine platforms and diseasesStrengthened partnership with Takeda in Japan, the third largest pharmaceutical market, with significant improvement in financial termsRaises full year 2025 revenue framework to between $975 mill

      5/8/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax to Participate in BofA Securities 2025 Health Care Conference

      GAITHERSBURG, Md., May 7, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced that it will participate in the BofA Securities 2025 Health Care Conference. Conference Details: Fireside Chat Date: Wednesday, May 14, 2025 Time: 3:00 – 3:30 p.m. Pacific Time (PT) Location: Las Vegas, NV Conference Event: Investor Meetings Date: Wednesday, May 14, 2025 A webcast of the fireside chat will be available on the Events & Presentations page of the Company's website at ir.novavax.com. A replay of the webcast will be available for 30 days. About NovavaxNovavax, Inc. (NASDAQ:NVAX) tackles some of the world's most significant health challenges by leveraging its scientific expertise in vaccines

      5/7/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan

      Improved financial terms for Novavax and streamlined operations will help both companies better meet the needs of the Japanese market Nuvaxovid®, a protein-based, non-mRNA COVID-19 vaccine, will continue to be available in Japan, the world's third largest pharmaceutical marketGAITHERSBURG, Md., May 5, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) has updated the terms of the previously announced collaboration and licensing agreement (CLA) with Takeda. The improved financial terms of the amended agreement for the development, manufacturing and commercialization of Nuvaxovid® in Japan include an upfront payment, payment related to the 2024/2025 season, annual milestones associated with regu

      5/5/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax to Report First Quarter 2025 Financial Results on May 8, 2025

      GAITHERSBURG, Md., May 1, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its first quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, May 8, 2025. Details of the event and replay are as follows: Conference call details: Date: May 8, 2025 Time: 8:30 a.m. U.S. ET URL to register phone: https://emportal.ink/43UHjFq Dial-in number: (800) 836-8184 (Domestic) or (+1) (646) 357-8785 (International) Webcast: ir.novavax.com/events Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.Participants

      5/1/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Appoints Charles Newton to Board of Directors

      GAITHERSBURG, Md., April 29, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced the appointment of Charles Newton to its board as an independent director. Mr. Newton brings extensive experience in public markets and healthcare investment banking to his role on the Novavax Board of Directors. "Charles brings a wealth of expertise across corporate finance and capital markets to Novavax," said John C. Jacobs, President and Chief Executive Officer, Novavax. "The knowledge he brings to our already experienced board will be invaluable as we continue to execute our corp

      4/29/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA

      Preliminary data showed Novavax's non-mRNA JN.1 COVID-19 vaccine induced lower frequency and severity of short-term side effects and impact on daily life compared with Pfizer-BioNTech mRNA vaccineFull results will be submitted for publication later this yearGAITHERSBURG, Md., April 15, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced preliminary results from the SHIELD-Utah study (Study of Healthcare Workers and First Responders Investigating Effects of Systemic and Local reactogenicity of COVID-19 Vaccine Doses in Utah) that showed Novavax's COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) targeting the JN.1 strain resulted in fewer and less severe reactogenicity symptoms, w

      4/15/25 7:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Announces Changes to Board of Directors

      James Young, PhD retires as Chair of the Board, Margaret McGlynn, RPh, appointedJohn Shiver, PhD appointed to board of directorsGAITHERSBURG, Md., March 11, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced that James Young, PhD, is retiring as Chair of the Board and Margaret McGlynn, RPh, has been appointed as his successor. The Company also appointed John Shiver, PhD, to its board as an independent director. Dr. Young made the decision to resign from the board effective March 10, 2025. He has served on Novavax's board since 2010 and as Chair since 2011. During

      3/11/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax to Participate in Upcoming March Investor Conferences

      GAITHERSBURG, Md., Feb. 27, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), today announced that the management team will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference: Fireside Chat Date: Tuesday, March 4, 2025 Time: 9:10 – 9:40 a.m. Eastern Time (ET) Location: Boston, MA   Conference Event: Investor Meetings Date: Tuesday, March 4, 2025 Leerink Partners 2025 Global Healthcare Conference: Presentation Date: Tuesday, March 11, 2025 Time: 3:40 – 4:10 p.m. ET Location: Miami Beach, FL   Conference Event: Investor Meetings Date: Tuesday, March 11, 2025 Jefferies Biotech on the Beach Summit: Conference Event: Investor Meetings Date: Wed

      2/27/25 4:05:00 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

      Transitioned lead commercial responsibility of Nuvaxovid™ COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in the fourth quarter of 2024 and $682 million for the full year 2024 Achieved $50 million milestone under Sanofi agreement associated with the pediatric clinical trial database lock for the first cohortCompleted $200 million sale of Czech Republic manufacturing facility to Novo Nordisk; reduces annual costs by approximately $80 millionAdvanced pipeline programs, based on proven and innovative technology platformEnded full year 2024 with over $1 billion in Cash and accounts receivablesProvides 2025 financial guidance and revenue framew

      2/27/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025

      GAITHERSBURG, Md., Feb. 20, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 27, 2025. Details of the event and replay are as follows: Conference call details: Date: February 27, 2025 Time: 8:30 a.m. U.S. ET URL to register phone: https://emportal.ink/3PsP11e Dial-in number: (800) 836-8184 (Domestic) or (+1) (646) 357-8785 (International) Webcast:   ir.novavax.com/events Participants can join the conference call without operator assistance by regist

      2/20/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Novavax Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Newton Charles W.

      4 - NOVAVAX INC (0001000694) (Issuer)

      4/29/25 8:08:08 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Newton Charles W.

      3 - NOVAVAX INC (0001000694) (Issuer)

      4/29/25 8:06:39 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Shiver John W.

      4 - NOVAVAX INC (0001000694) (Issuer)

      3/12/25 8:04:38 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Shiver John W.

      3 - NOVAVAX INC (0001000694) (Issuer)

      3/12/25 8:03:26 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and COO Trizzino John converted options into 28,890 shares and covered exercise/tax liability with 13,954 shares, increasing direct ownership by 28% to 68,061 units (SEC Form 4)

      4 - NOVAVAX INC (0001000694) (Issuer)

      3/11/25 4:34:48 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • EVP, CFO and Treasurer Kelly James Patrick converted options into 12,223 shares and covered exercise/tax liability with 5,904 shares, increasing direct ownership by 10% to 69,251 units (SEC Form 4)

      4 - NOVAVAX INC (0001000694) (Issuer)

      3/11/25 4:33:46 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by EVP, Chief Legal Officer Casey Mark J

      4 - NOVAVAX INC (0001000694) (Issuer)

      3/5/25 5:07:27 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Section 16 Draghia-Akli Ruxandra

      4 - NOVAVAX INC (0001000694) (Issuer)

      3/5/25 5:04:25 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by President and CEO Jacobs John C

      4 - NOVAVAX INC (0001000694) (Issuer)

      3/5/25 5:03:24 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by EVP, Chief Strategy Officer O'Hara Elaine

      4 - NOVAVAX INC (0001000694) (Issuer)

      3/5/25 5:02:21 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Novavax Inc. Financials

    Live finance-specific insights

    See more
    • Novavax Reports First Quarter 2025 Financial Results and Operational Highlights

      FDA feedback on COVID-19 BLA suggests pathway to approval upon alignment on study parameters for the postmarketing commitment requested by FDASHIELD-Utah study demonstrates that Nuvaxovid® resulted in fewer and less severe reactogenicity symptoms when compared to marketed mRNA vaccine; Nuvaxovid recipients experienced approximately 39% fewer symptoms on averageData presented at World Vaccine Congress showcases Matrix-M® utility when co-administered with a broad array of vaccine platforms and diseasesStrengthened partnership with Takeda in Japan, the third largest pharmaceutical market, with significant improvement in financial termsRaises full year 2025 revenue framework to between $975 mill

      5/8/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax to Report First Quarter 2025 Financial Results on May 8, 2025

      GAITHERSBURG, Md., May 1, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its first quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, May 8, 2025. Details of the event and replay are as follows: Conference call details: Date: May 8, 2025 Time: 8:30 a.m. U.S. ET URL to register phone: https://emportal.ink/43UHjFq Dial-in number: (800) 836-8184 (Domestic) or (+1) (646) 357-8785 (International) Webcast: ir.novavax.com/events Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.Participants

      5/1/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

      Transitioned lead commercial responsibility of Nuvaxovid™ COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in the fourth quarter of 2024 and $682 million for the full year 2024 Achieved $50 million milestone under Sanofi agreement associated with the pediatric clinical trial database lock for the first cohortCompleted $200 million sale of Czech Republic manufacturing facility to Novo Nordisk; reduces annual costs by approximately $80 millionAdvanced pipeline programs, based on proven and innovative technology platformEnded full year 2024 with over $1 billion in Cash and accounts receivablesProvides 2025 financial guidance and revenue framew

      2/27/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025

      GAITHERSBURG, Md., Feb. 20, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 27, 2025. Details of the event and replay are as follows: Conference call details: Date: February 27, 2025 Time: 8:30 a.m. U.S. ET URL to register phone: https://emportal.ink/3PsP11e Dial-in number: (800) 836-8184 (Domestic) or (+1) (646) 357-8785 (International) Webcast:   ir.novavax.com/events Participants can join the conference call without operator assistance by regist

      2/20/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights

      U.S. FDA removes clinical hold on Investigational New Drug application for COVID-19-Influenza Combination and stand-alone influenza vaccine candidatesAchieved total revenue of $85 million in the third quarter of 2024 Ended the third quarter of 2024 with $1 billion in cash and receivablesReceived authorization from U.S. FDA and European Commission for updated 2024-2025 formula COVID-19 vaccine in individuals aged 12 and olderOutlined R&D strategy based on its proven technology platformUpdates full year 2024 financial guidanceCompany to host conference call today at 8:30 a.m. ETGAITHERSBURG, Md., Nov. 12, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-base

      11/12/24 8:02:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024

      GAITHERSBURG, Md., Nov. 4, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its third quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Tuesday, November 12, 2024. Details of the event and replay are as follows: Conference call details: Date: November 12, 2024 Time: 8:30 a.m. U.S. ET URL to register phone: https://emportal.ink/3Y6irHG Dial-in number: (800) 836-8184 (Domestic) or (+1) (646) 357-8785 (International) Webcast: ir.novavax.com/events Participants can join the conference call without operator assistance by registering and entering

      11/4/24 4:30:00 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights

      Achieved total revenue of $415 million in the second quarter of 2024 and ended the period with $1.1 billion in CashFiled with the U.S. FDA and EMA for authorization of updated 2024-2025 formula COVID-19 vaccineReceived $570 million in upfront payment and equity investment from Sanofi; progressed operationalization of Sanofi partnershipPhase 3 trial initiation for COVID-19-Influenza Combination and stand-alone influenza vaccines planned for Q4 2024; data expected by mid-2025Company to host conference call today at 8:30 a.m. ETGAITHERSBURG, Md., Aug. 8, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announc

      8/8/24 8:02:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Operational Highlights on August 8, 2024

      GAITHERSBURG, Md., Aug. 1, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its second quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, August 8, 2024. Details of the event and replay are as follows: Conference call details: Date: August 8, 2024 Time: 8:30 a.m. U.S. ET URL to register phone: https://emportal.ink/3XTduSS Dial-in number: (800) 836-8184 (Domestic) or (+1) (646) 357-8785 (International) Webcast: ir.novavax.com/events  Participants can join the conference call without operator assistance by registering and entering the

      8/1/24 9:25:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Reports First Quarter 2024 Financial Results and Operational Highlights

      Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-MTM adjuvantThis agreement represents a potential multi-billion dollar revenue opportunity for Novavax including:$500 million upfront payment Approximately $70 million equity investment in NovavaxUp to $700 million in COVID-19 and combination product near-term milestones, plus ongoing tiered royalties on product salesUp to $200 million in milestones plus royalties for each new vaccine developed utilizing Novavax's Matrix-MTM adjuvantAnnounces addition of standalone influenza vaccine to P

      5/10/24 2:15:00 AM ET
      $NVAX
      $SNY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Novavax to Host Conference Call to Discuss First Quarter 2024 Financial Results and Operational Highlights on May 10, 2024

      GAITHERSBURG, Md., May 7, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its first quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Friday, May 10, 2024. Details of the event and replay are as follows: Conference call details: Date:                              May 10, 2024 Time:                                8:30 a.m. U.S. ET URL to register phone:      https://emportal.ink/3VNP8J5 Dial-in number:                  (888) 664-6383 (Domestic) or (+1) (416) 764-8650 (International) Webcast:      ir.novavax.com/events Participants can join t

      5/7/24 9:25:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Novavax Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Novavax Appoints Charles Newton to Board of Directors

      GAITHERSBURG, Md., April 29, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced the appointment of Charles Newton to its board as an independent director. Mr. Newton brings extensive experience in public markets and healthcare investment banking to his role on the Novavax Board of Directors. "Charles brings a wealth of expertise across corporate finance and capital markets to Novavax," said John C. Jacobs, President and Chief Executive Officer, Novavax. "The knowledge he brings to our already experienced board will be invaluable as we continue to execute our corp

      4/29/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Brian Rosen, Commercial Strategy Senior Executive, Appointed as Director of Capstone Companies, Inc.

      Capstone Companies, Inc. (OTCQB:CAPC) announced today the appointment of Brian Rosen as a non-employee director, effective January 20, 2025. Mr. Rosen has extensive experience in marketing, business development, contract negotiation and government relations as well as experience as a member of two public companies' management. He served as Senior Vice President, Global Market Access, Public Policy & Alliances (2021 - 2023), Senior Vice President, Commercial Strategy (2018 - 2021) and Vice President, Market Access, Policy, & Government Affairs (2015 - 2017) with Novavax, Inc. (NASDAQ:NVAX). Before Novavax, Inc., Mr. Rosen served as Chief Policy, Advocacy & Patient Services Officer (2014 -

      1/23/25 9:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development

      Ruxandra Draghia-Akli, MD, PhD brings more than 20 years of extensive clinical, corporate and global public health expertise to support Novavax's transition to an R&D-focused organizationDr. Draghia-Akli will be integral in strategically evaluating the Company's pipeline and opportunities for its Matrix-M™ adjuvant and protein-based technology platformGAITHERSBURG, Md., Sept. 25, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Ruxandra Draghia-Akli, MD, PhD, will join the Company in November 2024 as Executive Vice President and Head of Research & Development (R&D). Dr. Draghia-Akli brings m

      9/25/24 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Shah Capital nominates two highly qualified independent director candidates for Novavax

      Believes the two new nominated directors possess the necessary experience to tackle the underperformance of the business which will improve its share price       Shah Capital which owns 6.7% of Novavax, in a letter to the board says that the low share price reflects the board and management's failure to capitalize on Novavax's many significant competitive advantages and TAM opportunities The letter highlights that the underperformance is self-inflicted and is the result of reactive leadership and outdated and old-fashioned marketing RALEIGH, N.C., April 15, 2024 (GLOBE NEWSWIRE) -- Shah Capital, which owns approximately 6.7% of the outstanding common stock of Novavax (NASDAQ:NVAX), ha

      4/15/24 6:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Makes Changes to Executive Leadership Team to Enhance Focus on Delivery of Strategic Priorities

      New organizational structure for executive leadership team designed to facilitate a leaner and more focused approach to annual execution of business plansJohn Trizzino appointed to new Chief Operating Officer roleMark Casey to join as Chief Legal Officer and Corporate SecretaryGAITHERSBURG, Md., Nov. 17, 2023 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced changes to its executive leadership team designed to enhance focus on its strategic priorities and continue the evolution of the Company's scale and structure announced last week. John Trizzino will take on the newly created role of President and Ch

      11/17/23 7:15:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Names John C. Jacobs as New President & Chief Executive Officer

      Current President & CEO Stanley C. Erck will retire effective January 23 with plans to support the leadership transition in an advisory capacity Novavax is well-positioned to execute on its strategy, with global authorizations for its COVID-19 vaccine and continued clinical pipeline developmentGAITHERSBURG, Md., Jan. 9, 2023 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that John C. Jacobs will succeed Stanley C. Erck as President and Chief Executive Officer and a member of the Board of Directors. The transition will be effective as of January 23, 2023.

      1/9/23 9:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Appoints Rick Rodgers to Board of Directors

      GAITHERSBURG, Md., Nov. 1, 2022 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the appointment of Richard Rodgers, MBA to its board as an independent director. Mr. Rodgers brings extensive experience in biopharmaceutical management to his role on the Novavax Board of Directors. "Rick's deep experience in the pharmaceutical industry coupled with his extensive acumen in building rapidly growing companies and financial leadership will be invaluable as we continue the commercialization of our COVID-19 vaccine and expand our vaccine pipeline," said Stanley C.

      11/1/22 4:30:00 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Codexis Announces Appointment of Rahul Singhvi, Sc.D., to Board of Directors

      REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Rahul Singhvi, Sc.D., to its Board of Directors. Dr. Singhvi is a biotechnology industry veteran with more than three decades of research and development, operations and commercialization expertise across his time with Takeda Pharmaceutical Co., Novavax, Inc. and Merck & Co., Inc. He currently serves as the Chief Executive Officer of National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company, which he co-founded and built, with end-to-end manufacturing and digital s

      10/3/22 8:00:00 AM ET
      $CDXS
      $NVAX
      Major Chemicals
      Industrials
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Appoints Biopharmaceutical Veterans Jim Kelly as Chief Financial Officer and Nasir Egal, Ph.D., as Senior Vice President of Quality Assurance

      GAITHERSBURG, Md., Aug. 16, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Jim Kelly as Executive Vice President, Chief Financial Officer (CFO) and Treasurer, and Nasir Egal, Ph.D. as Senior Vice President, Quality Assurance. Mr. Kelly will report to Stanley C. Erck, President and Chief Executive Officer, and Dr. Egal will report to Rick Crowley, Executive Vice President and Chief Operations Officer. Mr. Kelly brings more than twenty-five years of industry experience in both commercial and clinical-stage companies to Novavax. He joins Novavax from Supernus Pharma

      8/16/21 8:50:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Announces Leadership Updates

      GAITHERSBURG, Md., April 13, 2021 /PRNewswire/ --  Novavax, Inc. (NASDAQ:NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the promotion of Gale E. Smith, Ph.D., to Senior Vice President, Discovery and Pre-Clinical Research and Chief Scientist, and the appointment of Troy Morgan as Senior Vice President, Chief Compliance Officer. The company also announced that Greg Covino will be stepping down as Chief Financial Officer (CFO) and will take on a new role as executive adviser to the company. Recognized as a pioneer in vaccine research, Dr. Smith is the senior inventor of the insect cell technology that serves as the basis of N

      4/13/21 6:42:00 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Novavax Inc. SEC Filings

    See more
    • Novavax Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - NOVAVAX INC (0001000694) (Filer)

      5/8/25 8:26:56 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Novavax Inc.

      10-Q - NOVAVAX INC (0001000694) (Filer)

      5/8/25 7:59:11 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

      8-K - NOVAVAX INC (0001000694) (Filer)

      5/5/25 9:25:23 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Novavax Inc.

      DEFA14A - NOVAVAX INC (0001000694) (Filer)

      4/30/25 6:01:08 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Novavax Inc.

      DEF 14A - NOVAVAX INC (0001000694) (Filer)

      4/29/25 8:51:59 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Inc. filed SEC Form 8-K: Leadership Update

      8-K - NOVAVAX INC (0001000694) (Filer)

      4/29/25 8:00:30 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - NOVAVAX INC (0001000694) (Filer)

      4/23/25 8:00:24 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - NOVAVAX INC (0001000694) (Filer)

      4/2/25 2:52:21 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - NOVAVAX INC (0001000694) (Filer)

      3/11/25 4:45:42 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement

      8-K - NOVAVAX INC (0001000694) (Filer)

      3/11/25 8:30:31 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Novavax Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    Novavax Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13G/A filed by Novavax Inc.

      SC 13G/A - NOVAVAX INC (0001000694) (Subject)

      11/12/24 4:46:17 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Novavax Inc.

      SC 13G/A - NOVAVAX INC (0001000694) (Subject)

      11/4/24 1:19:04 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Novavax Inc.

      SC 13G/A - NOVAVAX INC (0001000694) (Subject)

      7/10/24 6:16:55 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Novavax Inc.

      SC 13G/A - NOVAVAX INC (0001000694) (Subject)

      6/20/24 2:35:58 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Novavax Inc. (Amendment)

      SC 13D/A - NOVAVAX INC (0001000694) (Subject)

      5/20/24 6:09:08 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Novavax Inc. (Amendment)

      SC 13D/A - NOVAVAX INC (0001000694) (Subject)

      5/7/24 2:43:55 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Novavax Inc. (Amendment)

      SC 13D/A - NOVAVAX INC (0001000694) (Subject)

      4/15/24 12:18:22 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Novavax Inc.

      SC 13D - NOVAVAX INC (0001000694) (Subject)

      4/15/24 6:00:06 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Novavax Inc. (Amendment)

      SC 13G/A - NOVAVAX INC (0001000694) (Subject)

      3/7/24 4:34:19 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Novavax Inc.

      SC 13G - NOVAVAX INC (0001000694) (Subject)

      2/9/24 1:59:41 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BTIG Research initiated coverage on Novavax with a new price target

      BTIG Research initiated coverage of Novavax with a rating of Buy and set a new price target of $19.00

      2/28/25 7:28:04 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax downgraded by JP Morgan with a new price target

      JP Morgan downgraded Novavax from Neutral to Underweight and set a new price target of $8.00

      7/30/24 6:25:22 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax upgraded by BofA Securities with a new price target

      BofA Securities upgraded Novavax from Underperform to Neutral and set a new price target of $12.00 from $4.00 previously

      5/10/24 1:12:36 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax upgraded by JP Morgan

      JP Morgan upgraded Novavax from Underweight to Neutral

      5/10/24 9:29:58 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax upgraded by B. Riley Securities with a new price target

      B. Riley Securities upgraded Novavax from Neutral to Buy and set a new price target of $15.00

      8/9/23 8:30:54 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax downgraded by TD Cowen with a new price target

      TD Cowen downgraded Novavax from Outperform to Market Perform and set a new price target of $10.00 from $55.00 previously

      4/20/23 7:44:37 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded Novavax from Buy to Neutral and set a new price target of $10.00 from $29.00 previously

      3/1/23 7:29:41 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • B. Riley Securities reiterated coverage on Novavax with a new price target

      B. Riley Securities reiterated coverage of Novavax with a rating of Buy and set a new price target of $37.00 from $74.00 previously

      1/9/23 10:51:04 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright reiterated coverage on Novavax with a new price target

      H.C. Wainwright reiterated coverage of Novavax with a rating of Buy and set a new price target of $110.00 from $207.00 previously

      12/30/22 12:05:29 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies initiated coverage on Novavax

      Jefferies initiated coverage of Novavax with a rating of Hold

      12/2/22 8:18:23 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Novavax Inc. FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

      For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

      9/3/24 2:26:49 PM ET
      $NVAX
      $PFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

      For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

      8/30/24 2:26:48 PM ET
      $NVAX
      $PFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • October 3, 2023 - FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants

      For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO

      10/3/23 2:56:27 PM ET
      $NVAX
      $PFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • September 13, 2022 - FDA Roundup: September 13, 2022

      For Immediate Release: September 13, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Monday, the FDA reissued the Aug. 19, 2022, letter of authorization for Novavax COVID-19 Vaccine, Adjuvanted to revise the conditions of authorization related to the Vaccine Adverse Event Reporting System (VAERS) reporting requirements for vaccination pr

      9/13/22 2:34:10 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • July 13, 2022 - Coronavirus (COVID-19) Update: FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine, Adjuvanted

      For Immediate Release: July 13, 2022 Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the Novavax COVID-19 Vaccine, Adjuvanted for the prevention of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older.  “Authorizing an additional COVID-19 vaccine expands the available vaccine options for the preventi

      7/13/22 4:12:12 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care